Date: 2013-06-10
Type of information: Licensing agreement
Compound: Drosophila Schneider-2 cell-based technology platform - ExpreS2 - for protein production
Company: ExpreS2ion Biotechnologies (Denmark) Cancer Research UK’s London Research Institute (UK)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: ExpreS2ion Biotechnologies has developed a complete proprietary protein expression platform, ExpreS2, based on engineered Drosophila Schneider-2 (S2) cells to serve recombinant protein production needs in the biopharmaceutical industry as well as in academia. ExpreS2 allows quick access to proteins, excellent protein expression capability, scalability, applicability to high cell density production processes and regulatory friendliness. ExpreS2ion Biotechnologies is collaborating with teams developing manufacturing processes for malaria recombinant subunit vaccines. Expression of notoriously challenging malaria proteins in ExpreS2 platform has enabled progress in these projects that address a huge medical need. ExpreS2ion Biotechnologies offers technology platform licensing opportunities for use in R&D and commercial protein manufacturing.
Disease:
Details:
Financial terms:
Latest news: